Skip to content

Cardioneuroablation for Recurrent Vasovagal Syncope and Bradyarrhythmias: The CNA-FWRD Registry

Cardioneuroablation for the Management of Patients With Recurrent Vasovagal Syncope and Symptomatic Bradyarrhythmias: The CNA-FWRD Registry

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06166277
Acronym
CNA-FWRD
Enrollment
300
Registered
2023-12-12
Start date
2024-08-01
Completion date
2027-04-30
Last updated
2025-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vasovagal Syncope, AV Block-2Nd Degree-Type 1, Sinus Pause

Keywords

vasovagal syncope, av block, sinus pause, pacemaker, cardioneuroablation, radiofrequency ablation

Brief summary

The CNA-FWRD Registry is an international prospective observational multicenter registry of patients with symptomatic vasovagal syncope and bradyarrhythmias managed under routine care by medical therapy and radiofrequency catheter ablation of ganglionated plexi or permanent pacemaker implantation.

Detailed description

The CNA-FWRD Registry is an international prospective observational multicenter registry of patients with symptomatic vasovagal syncope and bradyarrhythmias managed under routine care by medical therapy and radiofrequency catheter ablation of ganglionated plexi or permanent pacemaker implantation. Major inclusion criteria for enrollment are history of VVS or symptomatic bradyarrhythmia, age \< 60 years, and evaluation by a physician and discussion about potential candidacy for radiofrequency cardioneuroablation or permanent pacemaker implantation for medically refractory symptoms. For analysis purposes, patients awaiting the intervention will remain in the control group and will cross-over to the procedural group after successful completion of radiofrequency cardioneuroablation procedure. The follow-up for the procedure group will start at completion of CNA procedure, but patients who eventually do not get the procedure will stay in the control group until the end of the study, with similar follow-up performed as for the patients undergoing RFCA procedure. If a patient in the control group undergoes permanent pacemaker placement, then the day after the procedure the patient will be removed from the control group for follow up.

Interventions

Cardioneuroablation procedure or permanent pacemaker placement

Sponsors

Rush University Medical Center
Lead SponsorOTHER

Study design

Observational model
CASE_CROSSOVER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years

Inclusion criteria

* symptomatic vasovagal syncope or symptomatic bradyarrhythmia refractory to behavioral and medical measures * age \< 60 years

Exclusion criteria

* age \> 60 years * intra-/infra-Hisian AV block * intrinsic sinus node disease * history of supraventricular tachycardia * history of ventricular tachycardia * presence of structural heart disease related * prior history of catheter ablation * presence of inheritable arrhythmic conditions * orthostatic hypotension on HUTT test * abnormal thyroid function levels * Proven indication for permanent pacemaker implantation

Design outcomes

Primary

MeasureTime frameDescription
Syncope3 yearsRecurrent syncope

Secondary

MeasureTime frameDescription
Syncope burden3 yearsNumber of syncopal episodes
Presyncope burden3 yearsNumber of pre syncopal episodes
Ablation induced change in heart rate1 yearDelta change in HR between pre-ablation and post-ablation
Time to first syncopal recurrence3 yearsTime to first syncope episode since enrollment
Quality of life before and 12 months after ablation1 yearQoL assessed by survey
Redo-ablation procedures3 yearsRedo-ablation procedures for primary outcomes
Atrial arrhythmias3 yearsDevelopment of new atrial arrhythmias
Complications associated with GP ablation1 yearMajor peri-procedural complications

Countries

United States

Contacts

Primary ContactAlexander Mazur, MD
alexander_mazur@rush.edu312-942-5020
Backup ContactJeanne du Fay de Lavallaz, MD
jeanne.dufaydelavallaz@gmail.com312-942-5000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026